Sign in with Google
bullish
Alphamab (康宁杰瑞) IPO: Strong R&D Capability and Innovative Platforms
643 Views24 Jul 2019 08:51
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange.
In this...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 9-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Santos (STO AU): XRG Consortium's Big Offer; Index Impact
- MV Global Junior Gold Miners Index Rebalance: Stocks at Their Highs
- Pop Mart (9992 HK): Beyond Blind Boxes -Jewellery Debut. Stock Up 200% YTD. Is It Still a Buy?
- MV Australia Equal Weight Index Rebalance: MinRes, Pilbara Deleted as Trade Nears A$300m
- MV Global Uranium & Nuclear Energy/Infra Index Rebalance: Double Inclusion for CGN Mining
Top Unpaywalled Insights
More »- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
- [IO Technicals 2025/24] Downward Momentum Lingers
- China A-Share Consumer Staples: An Analysis of the Opportunities Ahead
- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
x